| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLHDC1 |
| Uniprot No | Q8N7A1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-406aa |
| 氨基酸序列 | MADSQLFCVA EERSGHCAVV DGNFLYVWGG YVSIEDNEVY LPNDEIWTYD IDSGLWRMHL MEGELPASMS GSCGACINGK LYIFGGYDDK GYSNRLYFVN LRTRDETYIW EKITDFEGQP PTPRDKLSCW VYKDRLIYFG GYGCRRHSEL QDCFDVHDAS WEEQIFWGWH NDVHIFDTKT QTWFQPEIKG GVPPQPRAAH TCAVLGNKGY IFGGRVLQTR MNDLHYLNLD TWTWSGRITI NGESPKHRSW HTLTPIADDK LFLCGGLSAD NIPLSDGWIH NVTTNCWKQL THLPKTRPRL WHTACLGKEN EIMVFGGSKD DLLALDTGHC NDLLIFQTQP YSLLRSCLDC IGKNSIMLES QISLLPPKLL QQVLKKITFW AAANHREEQR VQKEETENKY QWISSN |
| 预测分子量 | 46,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KLHDC1重组蛋白的3篇虚构参考文献示例(仅供格式参考，内容非真实文献)：
---
1. **文献名称**：KLHDC1重组蛋白在卵巢癌细胞中的表达调控及功能研究
**作者**：Li et al.
**摘要**：本研究通过在大肠杆菌中重组表达KLHDC1蛋白，发现其通过调控Wnt/β-catenin信号通路促进卵巢癌细胞增殖和迁移，为卵巢癌靶向治疗提供了潜在靶点。
---
2. **文献名称**：KLHDC1与CUL2复合物的结构解析及其在泛素化中的作用
**作者**：Smith et al.
**摘要**：利用冷冻电镜技术解析了KLHDC1重组蛋白与CUL2的复合物结构，揭示了其作为E3泛素连接酶底物识别组件的分子机制，为开发相关小分子抑制剂奠定基础。
---
3. **文献名称**：KLHDC1重组蛋白在阿尔茨海默病模型中的异常聚集调控
**作者**：Wang et al.
**摘要**：通过体外重组KLHDC1蛋白实验，发现其与Tau蛋白异常聚集存在直接互作，抑制KLHDC1可减轻神经元损伤，提示其在神经退行性疾病中的病理作用。
---
注：以上文献信息为模拟生成，实际研究中需查询真实数据库(如PubMed)。
KLHDC1 (Kelch Domain Containing 1) is a protein-coding gene that plays roles in cellular processes such as protein degradation, signaling, and stress responses. Structurally, KLHDC1 contains a conserved Kelch domain, a β-propeller motif typically involved in protein-protein interactions by recognizing specific substrate motifs. This domain enables KLHDC1 to act as a substrate adaptor for Cullin-RING E3 ubiquitin ligase (CRL) complexes, particularly CUL2 or CUL3. facilitating the targeted ubiquitination and subsequent proteasomal degradation of bound proteins.
Emerging studies suggest KLHDC1 participates in regulating cell cycle progression, apoptosis, and DNA damage response. For example, it has been implicated in modulating the stability of proteins linked to mitotic control, though its exact physiological substrates remain under investigation. Dysregulation of KLHDC1 has been observed in certain cancers, with evidence pointing to both tumor-suppressive and oncogenic roles depending on cellular context. In ovarian and breast cancers, elevated KLHDC1 expression correlates with poor prognosis, potentially through interactions with oncogenic pathways like HIF-1α or p53.
Recombinant KLHDC1 protein is produced using heterologous expression systems (e.g., E. coli or mammalian cells) for functional studies. Purified KLHDC1 allows in vitro analysis of its binding partners, enzymatic activity in ubiquitination assays, and structural characterization. Researchers also employ it to generate antibodies or screen for small molecules targeting its substrate-binding interface. Despite progress, the full spectrum of KLHDC1’s biological functions and disease relevance requires further exploration, particularly its tissue-specific roles and post-translational modifications. Its dual role in cancer highlights the need for context-dependent studies to evaluate its potential as a therapeutic target.
×
